Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
Patel, 2020 | prospective cohort | cancelled by investigator | Surgisphere corporation : retracted publication | ||
IDEA, 2020 | prospective cohort | no control group |
Carvallo H medRxiv https://doi.org/10.1101/2020.09.10.20191619 |
||
Morgenstern, 2020 | single-arm | no control group |
Morgenstern J medRxiv https://doi.org/10.1101/2020.10.29.20222505 |
||
Million, 2020 | single-arm | no control group |
Million Travel Med Infect Dis 2020; :101738 10.1016/j.tmaid.2020.101738 |
||
Chamie-Quintero,, 2020 | population based cohort retrospective | no control group | No statistical analyses just a comparison of death between several peruvian states with or without mass distribution of ivermectin | ||
Delliere, 2020 | retrospective cohort | no clinically relevant endpoint | The main objective of this study was to determine invasive pulmonary aspergillosis (IPA) incidence in the COVID-19 patients admitted to the intensive care unit (ICU), describe the patient characteristics associated with its occurrence and evaluate the impact on prognosis. |
Delliere S et al. Clinical Microbiology and Infection 10.1016/j.cmi.2020.12.005 |
|
Alberici, 2020 | retrospective cohort | other | HCQ efficacy or safety evaluation wasn't a prespecified endpoint |
Alberici F Kidney Int 2020 Jul;98(1):20-26. 10.1016/j.kint.2020.04.030 |
|
Guerin, 2020 | non randomized controlled trial | other | no binary endpoints |
Guérin, Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1). |
|
Guerin, 2020 | non randomized controlled trial | other | no binary endpoints |
Guérin, Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1). |